Serum 25-hydroxyvitamin D levels do not correlate with asthma severity in a case-controlled study of children and adolescents by Menon, Jennifer et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Endocrinology/Diabetes Pediatric Divisions 
2012-07-27 
Serum 25-hydroxyvitamin D levels do not correlate with asthma 
severity in a case-controlled study of children and adolescents 
Jennifer Menon 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/peds_endocrinology 
 Part of the Endocrinology, Diabetes, and Metabolism Commons, Pediatrics Commons, and the 
Respiratory Tract Diseases Commons 
Repository Citation 
Menon J, Maranda L, Nwosu BU. (2012). Serum 25-hydroxyvitamin D levels do not correlate with asthma 
severity in a case-controlled study of children and adolescents. Endocrinology/Diabetes. https://doi.org/
10.1515/jpem-2012-0143. Retrieved from https://escholarship.umassmed.edu/peds_endocrinology/38 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Endocrinology/
Diabetes by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 DOI 10.1515/jpem-2012-0143   J Pediatr Endocr Met 2012; 25(7-8): 673–679
 Jennifer  Menon,  Louise  Maranda  and  Benjamin U.  Nwosu * 
 Serum 25-hydroxyvitamin D levels do not 
correlate with asthma severity in a case-controlled 
study of children and adolescents 
 Abstract  
Background: There is no consensus on the association 
between vitamin D and asthma.  
 Objective: To determine the relationship between 
25-hydroxyvitamin D [25(OH)D] levels and asthma 
symptom severity in children and adolescents.  
Methods: A retrospective, case-control study of 263 subj-
ects of ages 2 – 19 years with asthma who were compared 
to 284 non-asthmatic controls of similar ages. Subjects 
were excluded if they had diseases of calcium or vitamin D 
metabolism or were receiving calcium or vitamin D supple-
mentation. Serum 25(OH)D was measured in all subjects. 
Asthma symptom severity, usually stratified into 6 steps, 
was stratified into five steps  [1 – 5] based on the number 
and dose of controller medications used as outlined by 
the National Heart, Lung, and Blood Institute ’ s guidelines. 
Mean 25(OH)D values were compared between the asth-
matic patients and controls, as well as among the five steps 
of asthma symptom severity. Results were adjusted for age, 
sex, BMI, race and severity of asthma symptoms.  
Results: There was no difference in 25(OH)D between asth-
matic patients and controls (28.64  ±  10.09 vs. 28.42  ±  11.47, 
p  =  1.0). However, there was a significant difference 
in 25(OH)D between obese and non-obese asthmatic 
patients (23.33  ±  7.67 vs. 30.16  ±  10.20, p  <  0.0001), as well as 
obese and non-obese controls (24.56  ±  9.90 vs. 29.50  ±  11.66, 
p  =  0.003). Mean 25(OH)D levels did not vary significantly 
among the five steps of asthma symptom severity. 
 Conclusions: There were no differences in mean 25(OH)
D levels between asthmatic patients and controls. Mean 
25(OH)D level was significantly lower in both the obese 
asthmatic patients and obese controls. Asthma severity 
had no relationship to mean 25(OH)D levels. 
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 Introduction 
 Asthma is the most common chronic condition in children 
and adolescents in the USA. There is no consensus on the 
association between asthma and vitamin D. This immune-
mediated disease is characterized by reversible small 
airway inflammation leading to episodes of wheezing and 
respiratory distress. Despite the well-established National 
Asthma Education and Prevention Program set up by the 
National Heart, Lung, and Blood Institute (NHLBI) for the 
care and management of children and adolescents with 
asthma  (1) , the prevalence of the disease has continued 
to rise  (2) . There is a renewed interest in developing an 
adjunctive therapy to reduce the prevalence and severity 
of asthma. 
 This interest has led to the investigation of the 
immuno-modulatory properties of vitamin D as an anti-
inflammatory agent for the management of asthma  (3) . 
This is strengthened by epidemiological studies showing 
similarities in risk factors for both vitamin D deficiency and 
asthma. These similarities include African-American eth-
nicity, inner-city residence, obesity  (4) and an increased 
asthma prevalence in the northern geographical latitudes 
in the USA, where exposure to sunlight is limited  (5) . 
These epidemiological and demographic relationships 
between asthma and vitamin D have led some investiga-
tors to hypothesize that as populations grow more pros-
perous and more Westernized, more time is spent indoors 
with less exposure to sunlight, leading to vitamin D defi-
ciency, resulting in more asthma and allergy  (6) . 
 Vitamin D receptors (VDRs) have been identified on 
cells of the extra-skeletal system, especially those of the 
immune system, including human leukocytes, activated T 
cells and monocytes  (7, 8) . VDRs have also been identified 
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on respiratory epithelium and bronchial smooth muscle 
cells. It has been postulated that vitamin D could enhance 
airway remodeling after an asthma exacerbation  (3, 9 – 11) . 
Vitamin D possesses anti-inflammatory properties  (3) and 
enhances glucocorticoid response in steroid-resistance in 
asthma  (3, 12) . 
 Several studies have examined the beneficial effects 
of vitamin D on asthma symptom severity as well as its 
use as a surrogate marker of disease severity. In one large 
cohort study in asthmatic children in Costa Rica, Brehm 
et al.  (13) reported an inverse correlation between serum 
concentrations of 25-hydroxyvitamin D [25(OH)D] levels 
and markers of allergy and asthma severity. Another study 
from northern Italy showed a direct correlation between 
asthma control and serum 25(OH)D in a cohort of asth-
matic children  (14) . Other cross-sectional studies in chil-
dren have shown that serum 25(OH)D concentrations are 
directly correlated with pulmonary function parameters, 
such as forced expiratory volume in one second  (15) , and 
also inversely correlated with asthma severity and airway 
smooth muscle mass  (16) . 
 Goleva et al.  (17) reported a significant inverse cor-
relation between serum IgE and serum vitamin D levels 
in pediatric patients with asthma but not in adult asth-
matic patients. They also found significant associations 
between serum vitamin D levels and vitamin D-regulated 
targets and the patients ’ steroid responses in vitro, as well 
as steroid requirements in pediatric asthmatic patients 
but not in the adult asthmatic patients. These findings 
suggest that children with asthma might respond better to 
oral vitamin D supplementation than adults. 
 Some early effect studies have examined maternal 
25(OH)D levels and the effects of vitamin D supplementa-
tion in early life on the development of asthma. Morales 
et al.  (18) reported that higher maternal circulating 25(OH)
D concentrations in pregnancy were independently asso-
ciated with a lower risk of lower respiratory tract infections 
in offspring in the first year of life, but not with wheez-
ing or asthma in childhood. However, another study from 
the northeastern US demonstrated that a higher maternal 
intake of vitamin D during pregnancy may decrease the 
risk of recurrent wheeze in early childhood  (19) . 
 In contrast, other studies have shown no evidence for 
low 25(OH)D levels in asthmatic subjects when compared 
to controls, whereas others have linked vitamin D suffi-
ciency with adverse outcomes in asthma. A case-control 
study in two disparate adult populations in Europe did not 
find any significant difference in 25(OH)D levels between 
asthmatic patients and controls  (20) . Some studies have 
reported adverse associations between vitamin D and 
childhood eczema and asthma  (21) , and allergic diseases 
in adults  (22, 23) . Given all of the above differing conclu-
sions, the Institute of Medicine recently reviewed the 
health effects of vitamin D and found no conclusive evi-
dence for vitamin D supplementation in asthma and other 
extra-skeletal pathologies that have been associated with 
vitamin D deficiency  (24) . 
 We designed this retrospective, case-control study 
to further explore the relationship between asthma and 
vitamin D levels in children and adolescents. Our aims 
were to (A) determine if there was a significant difference 
in vitamin D levels between asthmatic patients and con-
trols, and (B) to determine if vitamin D levels were asso-
ciated with asthma symptom severity. Our hypothesis 
was that 25(OH)D levels would be lower in patients with 
asthma. 
 Methods 
 Subjects 
 We reviewed the medical records of children and adolescents of 
ages 2 – 19 years with a diagnosis of asthma at the Children ’ s Medical 
Center at the University of Massachusetts Medical Center between 
2007 and 2011. The study protocol was approved by the University 
of Massachusetts Institutional Review Board. Study subjects (n  =  263; 
119 males) were included if they had a diagnosis of asthma or exer-
cise-induced asthma and if they had a measured serum 25(OH)D le-
vel available. Patients were excluded if they had a diagnosis of any 
chronic lung disease other than the aforementioned diseases, such 
as cystic fi brosis, chronic lung disease of prematurity, bronchopul-
monary dysplasia or pulmonary fi brosis; a concurrent diagnosis of 
any disease that aff ects calcium or vitamin D metabolism, such as 
DiGeorge syndrome, pseudohypoparathyroidism, hypoparathyroi-
dism, hyperparathyroidism, rickets, renal failure, renal tubular aci-
dosis, hepatitis or infi ltrative liver diseases, history of vitamin D or 
calcium supplementation prior to the date of 25(OH)D measurement 
or were on continuous doses of oral corticosteroids for the control 
of any disease other than asthma. We further excluded pregnant or 
lactating females and patients who had 25(OH)D levels drawn du-
ring the course of an acute asthma exacerbation because patients 
undergoing asthma exacerbations do not meet the NHLBI ’ s criteria 
for well-controlled asthma. 
 A group of age-matched children and adolescents served as con-
trols. The controls were identifi ed from the available medical records 
at the Children ’ s Medical Center at the University of Massachusetts 
Medical Center between 2007 and 2011. Subjects were included in 
the control group (n  =  284; 117 males) if they did not have a diagnosis 
of asthma, exercise-induced asthma, or reactive airway disease, but 
had serum 25(OH)D levels available. Control subjects were excluded 
if they had a diagnosis of any chronic lung disease, such as asthma, 
cystic fi brosis, chronic lung disease of prematurity, bronchopulmo-
nary dysplasia, pulmonary hemosiderosis or pulmonary fi brosis, 
or diseases associated with calcium and vitamin D metabolism or if 
they were receiving calcium or vitamin D supplementation prior to 
the date of their serum 25(OH)D levels. We also excluded pregnant 
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asthmatic patients have the same requirements as a step 5 patient, in 
addition to oral systemic corticosteroids. None of our study patients 
met the criteria for step 6, as all study subjects who were receiving 
oral systemic corticosteroids were taking them for diseases other 
than asthma and were therefore excluded. 
 Statistics 
 Statistical analyses were performed using the SPSS Predictive Ana-
lytics Soft Ware v.19 (IBM Corporation, Somers, NY) and Microsoft  
Excel (2007). Means and standard deviations were calculated for 
descriptive summary statistics and 25(OH)D measurements. An-
thropometrics and 25(OH)D levels were compared using Student ’ s 
t-test. Seasons were compared using Fisher ’ s exact test. Data were 
expressed as mean  ±  SD. 
 Results 
 Subject characteristics 
 We identified 9445 asthmatic children and adolescents 
of ages 2 – 19 years in our database. Of these, 646 (6.84 % ) 
had serum 25(OH)D levels available. The mean 25(OH)D 
of this cohort was 28.81  ±  12.07 ng/mL. Of the subjects, 263 
[40.71 % of the asthmatic subjects with serum 25(OH)D 
levels, 2.78 % of all asthmatic children] met the inclusion 
and exclusion criteria of this study. A group of 284 simi-
larly aged non-asthmatic controls with available serum 
25(OH)D data was identified in the same database. 
 A comparison of the characteristics of the asthmatic 
and non-asthmatic groups showed no significant dif-
ferences in gender, height, weight, race or the season 
of vitamin D measurement. There were no differences 
in 25(OH)D levels in patients with asthma compared to 
the normal controls (28.64  ±  10.09 vs. 28.42  ±  11.47, p  =  1.0). 
The asthmatic subjects were older than the controls 
(14.34  ±  3.86 vs. 13.05  ±  4.23, p  =  0.0002). 
 However, when subjects were stratified into obese and 
non-obese groups based on BMIs of   <  95th percentile for 
non-obese, or   >  95th percentile for obese, (Table  1 ), there 
was a significant difference in 25(OH)D levels between 
obese and non-obese asthmatic patients (23.33  ±  7.67 vs. 
30.16  ±  10.20, p  <  0.0001) as well as obese and non-obese 
controls (24.56  ±  9.90 vs. 29.50  ±  11.66, p  =  0.003). In subse-
quent analysis, we stratified the subjects based on race 
into black and non-black. We found that that among the 
non-black asthmatic patients, the non-obese patients had 
significantly higher 25(OH)D levels compared to obese 
patients (30.13  ±  10.01 vs. 22.84  ±  7.85, p  <  0.0001), but 25(OH)
D levels did not differ significantly between the non-obese 
or lactating females and patients receiving systemic steroids. Ages 
of both study and control subjects was determined by the date of the 
25(OH)D measurement. Subjects were categorized into non-obese 
and obese categories using a body mass index (BMI) of   >  95 th percen-
tile to defi ne obesity  (25) . 
 Anthropometry 
 Height was measured to the nearest 0.01 cm using a wall-mounted 
stadiometer (Holtain Ltd, Crymych, Dyfed, UK). Weight was measu-
red to the nearest 0.01 kg using an upright scale. BMI was derived 
using the formula weight/height 2 (kg/m 2 ). All values were expressed 
as a standard deviation score (SDS) for age and gender based on the 
National Center for Health Statistics data  (26) . 
 Assays 
 Serum levels of 25(OH)D were analyzed using 25-hydroxy chemilumi-
nescent immunoassay (DiaSorin Liaison; Stillwater, MN), which has 
a 100 % cross-reactivity with both vitamin D 2 (the plant derived form 
of vitamin D called ergocalciferol) and vitamin D 3 (the animal-deri-
ved form known as cholecalciferol) and thus measures total serum 
25(OH)D content. Its functional sensitivity is 4 ng/mL (10 nmol/L), 
and its intra- and inter-assay coeffi  cients of variation are 5 % and 
8.2 % , respectively. 
 Vitamin D status 
 Vitamin D status was defi ned using 25(OH)D values based on the cri-
teria by the Pediatric Endocrine Society as follows: vitamin D defi -
ciency   <  15 ng/mL (37.5 nmol/L), insuffi  ciency 15 – 20 ng/mL (37.5 – 50 
nmol/L) and suffi  ciency   >  20 ng/mL (  >  50 nmol/L)  (27) . 
 Asthma symptom severity 
 Asthma symptom severity was determined based on the controller 
medications prescribed to the patients and recorded in their medical 
records as recommended by the NHLBI ’ s Guidelines for the Diagnosis 
and Management of Asthma. These guidelines provide a means of 
stratifying asthma symptom severity based on the number and type 
of controller medications and the dosages required to keep an asth-
matic patient in a well-controlled state  (1) . There are six steps [1 – 6] 
that represent increasing degrees of asthma symptom severity. Step 
1 is considered intermittent asthma and requires treatment with only 
a short-acting beta agonist as needed. Step 2 is considered mild per-
sistent asthma and is treated with a low-dose inhaled corticosteroid 
(ICS), cromolyn, theophylline or a leukotriene receptor antagonist 
(LTRA). Steps 3 and 4 are considered moderate persistent asthma. 
Step 3 asthmatic patients require treatment with either a medium-
dose ICS alone or a low-dose ICS in addition to either a long acting 
beta agonist (LABA), LTRA or theophylline. Step 4 asthmatic patients 
require medium-dose ICSs in addition to either a LABA, LTRA or 
theophylline. Steps 5 and 6 are considered severe persistent asthma. 
Step 5 asthmatic patients require high-dose ICS in addition to either 
a LABA, LTRA or theophylline for symptom control, whereas step 6 
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and obese black asthmatic patients (29.38  ±  11.71 vs. 
24.10  ±  8.44, p  =  0.2). Equally, among the controls, 25(OH)
D was significantly higher in the non-obese, non-black 
group vs. the obese, non-black group (30.45  ±  11.66 vs. 
26.21  ±  8.81, p  =  0.006), but did not differ between the non-
obese and obese black controls (22.63  ±  9.30 vs. 18.92  ±  11.62, 
p  =  0.3). There was neither a difference in 25(OH)D levels 
between asthmatic males vs. females (28.81  ±  10.74 vs. 
28.19  ±  9.80, p  =  0.6), nor between male and female controls 
(28.86  ±  11.83 vs. 28.11  ±  11.23, p  =  0.6). 
 There was no significant difference in mean 25(OH)
D levels when stratified according to the NHLBI ’ s asthma 
symptom severity  (1) . The mean  ±  standard deviations for 
serum 25(OH)D for the five asthma steps are as follows: 
28.30  ±  9.83 for step 1, 30.26  ±  10.64 for step 2, 28.25  ±  11.43 
for step 3, 26.60  ±  8.38 for step 4 and 25.00  ±  6.70 for step 5 
(p  =  0.5) (Figure  1 ). Table  2 shows the proportional analysis 
of vitamin D status of the asthmatic subjects based on the 
five steps of asthma symptom severity. 
 Discussion 
 Our case-control study did not detect any significant dif-
ference in 25(OH)D levels in patients with asthma com-
pared to the normal controls. Our sub-analysis showed 
that mean 25(OH)D levels were significantly lower in both 
the obese controls and asthmatic patients compared to 
their respective normal weight peers. We found no rela-
tionship between serum 25(OH)D concentrations and the 
steps of asthma severity. 
Asthmatics Non-asthmatics
Obese Non-obese p-Value Obese Non-obese p-Value
(n  =  59) (n  =  204) (n  =  62) (n  =  222)
Age, years 14.95  ±  3.17 14.16  ±  4.03    0.12 14.03  ±  3.23 12.78  ±  4.43    0.014
Males 25/59 96/204    0.53 25/62 94/230    0.92
(42.4 % ) (47.0 % ) (40.3 % ) (42.3 % )
Height SDS 0.02  ±  1.27  – 0.09  ±  1.31    0.58 0.51  ±  1.20  – 0.16  ±  1.13   <  0.0001
Weight SDS 2.05  ±  0.55 0.17  ±  1.18   <  0.0001 2.34  ±  0.56  – 0.02  ±  1.10   <  0.0001
BMI SDS 2.10  ±  0.29 0.32  ±  0.85   <  0.0001 2.23  ±  0.36 0.06  ±  1.03   <  0.0001
Race (non-black) 49/59 180/204    0.30 48/62 195/222    0.04
(83.0 % ) (88.0 % ) (77.4 % ) (87.8 % )
Serum 25(OH)D 23.33  ±  7.67 30.16  ±  10.20   <  0.0001 24.56  ±  9.90 29.50  ±  11.66    0.003
Season (Summer and Autumn) 37/59 108/204    0.18 44/62 125/222    0.04
(62.7 % ) (52.9 % ) (71.0 % ) (56.3 % )
 Table 1   Comparison of the body mass index adjusted characteristics of asthmatic patients and controls. 
 SDS, standard deviation score; 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index. 
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 Figure 1   Box plots showing no significant differences in mean 
25-hydroxyvitamin D levels between the controls and asthmatic 
patients stratified according to the five steps of asthma symptom 
severity. 
 Several studies have investigated the relationship 
between vitamin D and asthma in children  (13 – 16) and 
adults  (20) with conflicting results. Our finding of no sig-
nificant difference in mean 25(OH)D level between asth-
matic patients and controls is consistent with the findings 
from two case control studies by Devereux et al.  (20) and 
Goleva et al.  (17) , but differed from the results of Brehm 
 (13) , Chinellato et al.  (14) , Alyasin et al.  (15) and Gupta 
et al.  (16) . Brehm et al.  (13) compared the proportions of 
616 asthmatic subjects of ages 6 – 14 years who meet the cri-
teria for vitamin D sufficiency (  >  30 ng/mL), insufficiency 
(20 – 30 ng/mL) and deficiency (  <  20 ng/mL). They found 
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that lower serum 25(OH)D levels were associated with 
increased asthma severity as determined by pulmonary 
function testing (PFT) and frequency of asthma-related 
hospitalizations. This study found a significant inverse 
correlation between serum 25(OH)D levels and frequency 
of asthma exacerbations. However, unlike our study, it did 
not employ a case-control model to investigate the differ-
ences in mean 25(OH)D levels between asthmatic patients 
and controls. 
 In a cross-sectional study of a cohort of 75 asthmatic 
Italian children aged 5 – 11 years, Chinellato et al.  (14) found 
that the asthmatic children with higher serum 25(OH)
D levels had better perceived control of their symptoms 
compared to asthmatic patients with lower serum 25(OH)
D levels. This study also showed that, after stratifying 
the asthmatic patients into controlled, partly controlled 
and uncontrolled groups, serum 25(OH)D levels were 
significantly higher in the controlled group compared to 
the partly controlled group. This study was similar to our 
study because it was designed to investigate the relation-
ship between serum 25(OH)D levels and asthma severity. 
However, our stratification of asthma severity was based 
on controller medications and their dosages as outlined 
by the NHLBI ’ s guidelines  (1) , whereas the study by 
Chinellato et al. categorized severity based on the Global 
Initiative for Asthma guidelines. 
 Gupta et al.  (16) evaluated the relationship between 
serum 25(OH)D and asthma severity by comparing the 
median 25(OH)D levels of subjects with severe steroid 
resistant asthma, moderate asthma and non-asthmatic 
controls, as well as the frequency of vitamin D deficiency 
defined as serum 25(OH)D levels of   <  20 ng/mL (  <  50 
nmol/L) in the study. They reported significantly lower 
serum 25(OH)D levels in patients with steroid-resistant 
asthma compared with those with moderate asthma and 
non-asthmatic controls. They also found a higher preva-
lence of vitamin D deficiency and insufficiency in subjects 
with steroid resistant asthma. Alyasin et al.  (15) compared 
the mean serum 25(OH)D levels of patients of ages 6 – 18 
years in Iran. They found a significant difference in mean 
25(OH)D levels between 50 asthmatic patients and 50 age-
matched controls. 
 Some studies have reached opposite conclusions. 
Devereux et al.  (20) reported in a case-control study involv-
ing 80 asthmatic patients and 80 controls in two separate 
centers in Europe, Aberdeen (latitude 57 ° N) and Norwich 
(latitude 52 ° N), that there was no significant difference in 
serum 25(OH)D concentration between asthmatic patients 
and controls overall, or in Aberdeen or Norwich. In a case-
control study of both pediatric and adult patients with 
asthma, Goleva et al.  (17) noted no significant difference 
in the prevalence of vitamin D deficiency/insufficiency in 
their asthmatic group and normal controls. Hypponen et 
al. reported that regular high dose (   ≥   2000 IU/d) vitamin 
D supplementation during infancy has been associated 
with increased likelihood of atopy and allergic rhinitis at 
31 years  (22) , whereas Gale et al. showed that high (  >  30 
ng/mL) maternal serum 25(OH)D levels during pregnancy 
were associated with an increased likelihood of childhood 
eczema at 9 months and asthma at 9 years  (21) . Thus, 
there is no consensus on the relationship between vitamin 
D and asthma. 
 The finding of a lack of relationship between vitamin 
D and asthma in our study is consistent with the report by 
Devereux et al.  (20) , but differed from the conclusions of 
other studies that showed a relationship between serum 
25(OH)D concentrations and asthma symptom severity 
 (12, 13) . These association studies suggest that vitamin 
D could exert some beneficial effects in the treatment of 
steroid-resistant patients with asthma  (3) . This concept 
of a steroid-sparing effect of vitamin D was informed 
from a study that reported that the addition of vitamin 
D and dexamethasone to cultures of CD4  +  T regulatory 
cells from steroid resistant asthmatic patients enhanced 
Step 1 Step 2 Step 3 Step 4 Step 5
(n  =  138) (n  =  61) (n  =  44) (n  =  10) (n  =  10)
Mean 25(OH)D 28.30  ±  9.83 30.26  ±  10.64 28.25  ±  11.43 26.60  ±  8.38 25.00  ±  6.7
Vitamin D sufficient 114/138 (82.61 % ) 50/61 33/44 8/10 9/10
(   ≥   20 ng/mL) (81.97 % ) (75.00 % ) (80.00 % ) (90.00 % )
Vitamin D insufficient 15/138 (10.87 % ) 8/61 6/44 0/10 1/10
(16 – 19 ng/mL) (13.11 % ) (13.64 % ) (0 % ) (10.00 % )
Vitamin D deficient 9/138 3/61 5/44 2/10 0/10
(   ≤   15 ng/mL) (6.52 % ) (4.92 % ) (11.36 % ) (20.00 % ) (0 % )
 Table 2   Proportional Analysis of Vitamin D status across the five steps of asthma symptom severity. 
 25(OH)D ,  25-hydroxyvitamin D 
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interleukin-10 secretion from these cells to levels com-
parable to those from cells of steroid-sensitive patients 
treated with dexamethasone alone  (28) . However, some 
experiments in knock out (KO) mice do not support this 
association. Wittke et al.  (29) conducted an experimental 
allergic asthma induction in VDR KO mice and wild-type 
(WT) mice. The WT mice developed asthma as expected, 
but the KO did not. The administration of 1,25-dihydroxy-
vitamin D to the WT mice had no effect on asthma sever-
ity. The authors explained that the inability of the VDR 
KO mice to develop asthma was due to a failure of the 
lung micro-environment to attract pathogenic cells to the 
lungs rather than a failure of the priming and activation of 
immune cells. This finding is supported by a recent study 
that showed that the inability of VDR KO mice to develop 
airway hyperreactivity is a result of defective invariant 
natural killer cells and not due to defective Th2 cells  (30) . 
Furthermore, even though some studies have described 
an association between VDR genetic polymorphisms and 
asthma, this association has not been replicated in subse-
quent experiments  (6) . Therefore, the role of vitamin D on 
asthma symptom severity is inconclusive. 
 Our study showed that that mean 25(OH)D levels were 
significantly lower in both the obese controls and asth-
matic patients compared to their respective normal weight 
peers. This is consistent with earlier reports of vitamin D 
deficiency in obese individuals  (31 – 34) . The etio logy of 
vitamin D deficiency in obesity is unclear. Proposed causa-
tive factors include poor general nutrition, which results in 
low intake of vitamin D-containing foods such as salmon, 
inadequate exposure to sunlight and the sequestration of 
vitamin D in fat stores in obese individuals, which makes 
vitamin D unavailable for biological activities  (32) . 
 When compared to other studies that detected a sig-
nificant difference between asthmatic groups and con-
trols, our study of 263 asthmatic patients and 284 controls 
was sufficiently powered to detect any significant differ-
ence in 25(OH)D levels between the asthmatic patients 
and normal controls and any correlation with asthma 
severity. A similar case control study involving 50 asth-
matic children and 50 controls found a significant dif-
ference in 25(OH)D levels and also a significant inverse 
correlation with asthma severity  (15) . However, another 
study  (20) , powered to detect an 18 % difference in total 
25(OH)D levels failed to detect either a significant differ-
ence in 25(OH)D levels or a correlation with asthma sever-
ity in a similar case-control study in 80 asthmatic adults 
and 80 controls. A third case-control study involving 
children and adults reported a non-significant difference 
in 25(OH)D levels between 103 asthmatic patients and 
102 controls. This study, however, showed a significant 
inverse association between vitamin D and serum IgE, as 
well as vitamin D and daily inhaled corticosteroid dose in 
the pedia tric asthma group only  (17) . Among the non case-
control studies that reported significant inverse correla-
tion with asthma severity, one study evaluated 616 asth-
matic patients  (13) , another studied 75 asthmatic patients 
 (14) , whereas a third study investigated 86 asthmatic 
patients  (16) . Therefore, more carefully designed studies 
are needed to clarify the relationship between asthma 
seve rity and vitamin D status. 
 There are a number of limitations to be considered in 
the interpretation of our results. The first shortcoming is 
the cross-sectional design of the study which makes it dif-
ficult to establish causality. We also had a small sample 
size for the asthma steps 4 and 5. Such a sample size 
would be inadequate to detect subtle differences between 
the groups and could have resulted in type 2 error. In 
contrast, we had a representative number of patients in 
asthma steps 1, 2, and 3 to accurately assess the relation-
ship between vitamin D and asthma symptom severity 
in these steps. Another factor to take into consideration 
in interpreting our results is the accuracy of documenta-
tion of patients ’ disease state. In addition to documented 
asthma exacerbations and prescriptions filled for these 
exacerbations, we relied on physician ’ s documentation of 
the patients ’ medications as a means of evaluating asthma 
symptom severity. There was neither a way to confirm 
patients ’ compliance with the listed medications, nor 
was there a way to know if there had been recent changes 
to patients ’ medications based on changes in symptom 
severity. Some of the strengths of this study include the 
fact that the case-control design enabled us to evaluate a 
large cohort of patients with asthma and compared their 
data to a control group. We also used the NHLBI criteria 
for the delineation of asthma symptom severity. 
 In conclusion, we did not detect any significant differ-
ences in 25(OH)D levels between asthmatic patients and 
their age-matched controls. We noted that mean 25(OH)
D levels were significantly lower in both the obese con-
trols and asthmatic patients compared to their respective 
normal weight peers. We found no relationship between 
serum 25(OH)D concentrations and the NHLBI ’ s steps of 
asthma severity. Our study lends support to the Institute 
of Medicine ’ s recent position that there was no conclusive 
evidence for vitamin D supplementation in asthma  (24) . 
Randomized controlled trials of vitamin D supplemen-
tation in asthma are warranted to determine the role of 
vitamin D on asthma symptom severity. 
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